An Open Label, Single-Centre, Phase II Study for Radiosensitization of AVASTIN(R) (Bevacizumab) With Stereotactic Body Radiotherapy (SBRT) for Colorectal Liver Metastasis (SBRT Avastin)

Trial Profile

An Open Label, Single-Centre, Phase II Study for Radiosensitization of AVASTIN(R) (Bevacizumab) With Stereotactic Body Radiotherapy (SBRT) for Colorectal Liver Metastasis (SBRT Avastin)

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2016

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Colorectal cancer; Liver metastases
  • Focus Pharmacodynamics; Proof of concept
  • Acronyms SBRT-Avastin
  • Most Recent Events

    • 29 Mar 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov
    • 13 Apr 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top